Active, not recruitingPhase 4NCT06499948
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)
Studying Alport syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stefan Lujinschi
- Intervention
- Treatment with Spironolactone followed by Dapagliflozin followed by their combination(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Fundeni Clinical Institute, Bucharest, Sector 2, Romania
Collaborators
Carol Davila University of Medicine and Pharmacy · Institutul Clinic Fundeni
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06499948 on ClinicalTrials.govOther trials for Alport syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07211685BAY3401016; Biomarker Study AlportBayer
- ACTIVE NOT RECRUITINGNCT06226896Effects of Dapagliflozin on Progression of Alport SyndromeNanjing University School of Medicine
- RECRUITINGNCT06526741ASF Alport Patient RegistryAlport Syndrome Foundation
- ACTIVE NOT RECRUITINGPHASE2NCT04573920Atrasentan in Patients With Proteinuric Glomerular DiseasesNovartis Pharmaceuticals
- RECRUITINGNCT04947813Genotype-Phenotype Correlations in Patients With Alport SyndromeXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT05927467Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02378805Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeUniversity Hospital Goettingen